Automated Point-of-Care CAR T-Cell Fabrication & Democratization

MIDI’s latest White Paper describing advancements their team engineered in the biopharma fabrication space: Automated Point-of-Care CAR T-Cell Fabrication & Democratization . In particular it reveals a shift from centralized to point-of-care manufacturing and how closed system automation plays a pivotal role in making this revolutionary therapy accessible to all.
Related Reading
Resource / Digital Health / Government & Legislative Affairs
AdvaMed® 2025 Membership Has Its Privileges: Advocacy Wins for Medtech Members
March 3, 2026
AdvaMed 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.
Resource / Artificial Intelligence (AI) / Coverage & Payment / Digital Health / Regulatory Affairs
AdvaMed® Comment Letter to ASTP/ONC: Accelerating AI Adoption in Clinical Care
February 24, 2026
AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical devices transform patient care, outdated regulatory, coverage, and privacy frameworks are slowing the pace of adoption.
News / Diabetes / Digital Health
Dexcom’s Jake Leach Named Chair of AdvaMed’s Diabetes Sector
February 23, 2026
WASHINGTON—AdvaMed, the MedTech Association®, today announced that Jacob “Jake” Leach, President and Chief Executive Officer at Dexcom, will serve as the next chair of the AdvaMed Diabetes Sector, succeeding Chris Scoggins, Executive Vice President of Diabetes Care at Abbott. The AdvaMed Diabetes Sector represents the world’s leading companies producing technology across the spectrum of diabetes care.
Blog / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access
Heart Month: Why Sleep Apnea Belongs at the Center of Cardiovascular Care
February 13, 2026
February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.
News / Diagnostics / Digital Health / Medical Imaging / Regulatory Affairs
AdvaMed Receives RAPS Accreditation for Medical Device Submissions Workshop Series (February 2026 in Washington, D.C.)
February 4, 2026
WASHINGTON, D.C.—AdvaMed, the world’s largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).
Blog / Artificial Intelligence (AI) / Diagnostics / Digital Health / Health Access
The Insight Series: AI & Digital Health
January 30, 2026
AdvaMed Digital Health Tech division member companies include world leaders in developing AI-enabled solutions to improve health and care, from diagnosis to treatment, clinical decision support, and wearables to wellness. “The Insight Series: AI & Digital Health” will feature company experts, answering pressing questions to inform policymakers and the public about how AI and digital health are transforming care and delivery. Our inaugural entry is a conversation between Melissa Cha of Amazon and Taha Kass-Hout of GE HealthCare.
Blog / Diagnostics / Digital Health / Regulatory Affairs / Standards
Honoring Janet E. Trunzo: A Legacy That Shaped Modern Medtech Regulation
January 29, 2026
After 30 years at AdvaMed, Janet E. Trunzo, Senior Advisor to the President and Senior Executive Vice President of Technology and Regulatory Affairs, will retire on January 31, 2026. Her tenure has fundamentally shaped how medical devices are regulated in the United States and globally, establishing frameworks and standards that continue to govern the field today.
Blog / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access / Medical Imaging
Why the Health Tech Investment Act Matters: Peter Weems Breaks Down What This Means for Patients
January 26, 2026
In a new video developed in partnership with Patients Rising, AdvaMed’s Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.